Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
distributed in 34.6%, 30.8%, 15.4%, and 19.2% in Liraglutide, semaglutide, dulaglutide, and control groups, respectively
Never share your pen with others, even if you change the needle
None of these outcomes are acceptable when you are injecting something into your body
Reflecting on the clinical implications, St-Pierre says that the findings support cautious use of GLP-1 RAs in selected patients with IBD when prescribed for approved metabolic indications, with appropriate counselling and monitoring. At the same time, she noted that the findings highlight substantial evidence gaps and believes future research should move beyond proxy outcomes and incorporate prospective, IBD-specific designs that integrate objective inflammatory measures with robust metabolic phenotyping. Moreover, there should be special considerations on the effects of GLP-1 RAs on body composition of patients with IBD, she adds
US$ 29.89
US$ 25.20
US$ 20.51
